A Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis

Elan Pharmaceuticals

Status and phase: Terminated; Phase 1

Conditions: Multiple Sclerosis

Treatments: Drug: ELND002

Study type: Interventional

Funder types: Industry

Identifiers

NCT01318421

ELND002-MS153

Details and patient eligibility

About

The purpose of this study is to evaluate the long-term safety and tolerability of ELND002 in patients with multiple sclerosis (MS) after participation in study MS103.

Enrollment: 12 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• This study is open only to subjects who have completed the week 12 visit in study ELND002-MS103 while taking their assigned dose of study drug.

Exclusion criteria

• Subject has no new medical contraindications to continue participation in the study.

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

12 participants in 1 patient group

ELND002

Experimental group

Description:

ELND002 sc injection

Treatment:

Drug: ELND002